Biotronik has announced final enrolment in the BIOMAG-I clinical trial by Michael Haude (Rheinland Klinikum, Neuss, Germany) the study’s coordinating clinical investigator and the principal investigator Javier Escaned (Hospital Universitario Clínico San Carlos, Madrid, Spain. The prospective single-arm study assesses the safety and clinical performance of Dreams 3G resorbable magnesium scaffold (RMS).
“Based on my extensive experience with resorbable magnesium scaffolds, Dreams 3G represents a very promising evolution for resorbable technology. With its larger size matrix, thinner struts and improved mechanical performance, Dreams 3G has the potential to provide a broader range of clinical benefits than previously available scaffolds,” said Haude. “The BIOMAG-I study is investigating whether these design improvements will translate into the expected clinical benefits. The study has now achieved a major milestone by completing the enrolment, primary endpoint data on in-scaffold late lumen loss at six-month follow up are intended to be presented later this year.”
A total of 14 clinics in eight European countries are taking part in the BIOMAG-I clinical trial. The patient cohort includes 116 patients aged between 18 and 80 years with single de novo lesions in up to two coronary arteries. The study will run for a total of three years, assessing the primary endpoint of in-scaffold late lumen loss at six months, with follow-ups at 12, 24 and 36 months.
“Our resorbable magnesium scaffold technology for coronary artery disease has proven over recent years to be a valuable and safe alternative treatment option to permanent cobalt-chromium drug eluting stents (DES),” said Alexander Uhl, president vascular Intervention at Biotronik. “Our current RMS device in the market—Magmaris—showed excellent five-year clinical outcomes, comparable with contemporary drug-eluting stents. With our next RMS generation, we are confident that we will be able to provide a competitive treatment alternative to DES, solving the shortcomings of current DES permanent implants providing all the benefits of a ´leave nothing behind´ strategy. We expect this device to set the future standard for resorbable technology.”
Following the Magmaris RMS, the Dreams third-generation device is Biotronik’s newest resorbable solution made from proprietary Biomag magnesium alloy. The implant supports the patient’s vessel for a limited period only, which is critical for vessel healing. Approximately 12 months after the implantation the magnesium is resorbed.
Source CardiovascularNews
Duc Tin Clinic
Tin tức liên quan
Performance diagnostique de l’interféron gamma dans l’identification de l’origine tuberculeuse des pleurésies exsudatives
A Mixed Phenotype of Airway Wall Thickening and Emphysema Is Associated with Dyspnea and Hospitalization for Chronic Obstructive Pulmonary Disease.
Radiological Approach to Asthma and COPD-The Role of Computed Tomography.
Significant annual cost savings found with UrgoStart in UK and Germany
Thrombolex announces 510(k) clearance of Bashir catheter systems for thromboembolic disorders
Phone: (028) 3981 2678
Mobile: 0903 839 878 - 0909 384 389